Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival

被引:82
作者
Andersen, NF
Standal, T
Nielsen, JL
Heickendorff, L
Borset, M
Sorensen, FB
Abildgaard, N
机构
[1] Aarhus Univ Hosp, Aarhus Hosp, Dept Haematol, DK-8000 Aarhus C, Denmark
[2] Norwegian Univ Sci & Technol, Inst Canc Res & Mol Med, Trondheim, Norway
[3] Aarhus Univ Hosp, Aarhus Hosp, Dept Clin Biochem, Aarhus, Denmark
[4] Aarhus Univ Hosp, Aarhus Hosp, Dept Pathol, Aarhus, Denmark
[5] Odense Univ Hosp, Dept Haematol, Odense, Denmark
关键词
multiple myeloma; angiogenesis; angiogenic factors; syndecan-1; prognostic factors;
D O I
10.1111/j.1365-2141.2004.05299.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiogenesis is a complex process involved in the proliferation and 5 and partly triggered by the secretion of metastasis of malignant tumours, various angiogenic factors by tumour cells or cells in the stromal environment. We investigated the correlation between bone marrow angiogenesis, estimated as microvessel density (MVD), and interleukin-6 (IL-6), basic fibroblastic growth factor (bFGF), hepatocyte growth factor (HGF) and syndecan-1 in 67 patients with newly diagnosed multiple myeloma, and evaluated the prognostic value of these parameters. Circulating levels of IL-6, bFGF, HGF and syndecan-1 were significantly higher in patients than in controls. Moreover, in patients, bone marrow levels of bFGF, HGF and syndecan-1 were higher than peripheral blood levels. Positive correlations were found between MVD and syndecan-1 blood levels (r 0-33, P = 0-017), syndecan-1 bone marrow levels (r = 0-49, P 0(.)046) and HGF blood levels (r = 0(.)36, P = 0(.)008) respectively. High MVD and high blood levels of IL-6, HGF and syndecan- 1 were predictive of a shorter survival. In a multivariate survival analysis MVD and blood levels of IL-6 retained independent prognostic significance, while in a survival analysis without MVD the peripheral blood levels of HGF and syndecan- I were strong independent prognostic factors.
引用
收藏
页码:210 / 217
页数:8
相关论文
共 55 条
[41]  
RIDLEY RC, 1993, BLOOD, V81, P767
[42]  
Rosen E M, 1991, EXS, V59, P194
[43]  
Schaar CG, 1999, BRIT J HAEMATOL, V107, P132
[44]   Serum syndecan-1: a new independent prognostic marker in multiple myeloma [J].
Seidel, C ;
Sundan, A ;
Hjorth, M ;
Turesson, I ;
Dahl, IMS ;
Abildgaard, N ;
Waage, A ;
Borset, M .
BLOOD, 2000, 95 (02) :388-392
[45]   High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity [J].
Seidel, C ;
Borset, M ;
Hjertner, O ;
Cao, DJ ;
Abildgaard, N ;
Hjorth-Hansen, H ;
Sanderson, RD ;
Waage, A ;
Sundan, A .
BLOOD, 2000, 96 (09) :3139-3146
[46]   Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma [J].
Seidel, C ;
Borset, M ;
Turesson, I ;
Abildgaard, N ;
Sundan, A ;
Waage, A .
BLOOD, 1998, 91 (03) :806-812
[47]   Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma [J].
Sezer, O ;
Niemöller, K ;
Eucker, J ;
Jakob, C ;
Kaufmann, O ;
Zavrski, I ;
Dietel, M ;
Possinger, K .
ANNALS OF HEMATOLOGY, 2000, 79 (10) :574-577
[48]   Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican [J].
Steinfeld, R ;
VanDenBerghe, H ;
David, G .
JOURNAL OF CELL BIOLOGY, 1996, 133 (02) :405-416
[49]   Requisite role of Angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis [J].
Suri, C ;
Jones, PF ;
Patan, S ;
Bartunkova, S ;
Maisonpierre, PC ;
Davis, S ;
Sato, TN ;
Yancopoulos, GD .
CELL, 1996, 87 (07) :1171-1180
[50]  
Turesson I, 1999, BRIT J HAEMATOL, V106, P1005